Diez-Perez, Adolfo, Hooven, Frederick H., Adachi, Jonathan D., Adami, Silvano, Anderson, Frederick A., Boonen, Steven, Chapurlat, Roland, Compston, Juliet E., Cooper, Cyrus, Delmas, Pierre, Greenspan, Susan L., Lacroix, Andrea Z., Lindsay, Robert, Netelenbos, J. Coen, Pfeilschifter, Johannes, Roux, Christian, Saag, Kenneth G., Sambrook, Philip, Silverman, Stuart, Siris, Ethel S., Watts, Nelson B., Nika, Grigor and Gehlbach, Stephen H.
Regional differences in treatment for osteoporosis: The global longitudinal study of osteoporosis in women(GLOW)
Bone, 49, (3), . (doi:10.1016/j.bone.2011.05.007). (PMID:21605715).
Full text not available from this repository.
Among 58,009 women, current anti-osteoporosis medication use was lowest in Northern Europe (16%) and highest in USA and Australia (32%). Between 48% (USA, Southern Europe) and 68% (Northern Europe) of women aged ? 65 years with a history of spine or hip fracture since age 45 were untreated. Among women with osteoporosis, the percentage of treated cases was lowest in Europe (45–52% versus 62–65% elsewhere). Women with osteopenia and no other risk factors were treated with anti-osteoporosis medication most frequently in USA (31%) and Canada (31%), and least frequently in Southern Europe (12%), Northern Europe (13%), and Australia (16%). After adjusting for risk factors, US women were threefold as likely to be treated with anti-osteoporosis medication as Northern European women (odds ratio 2.8; 95% confidence interval 2.5–3.1) and 1.5 times as likely to be treated as Southern European women (1.5, 1.4–1.6). Up to half of women reporting previous hip or spine fracture did not receive treatment.
Actions (login required)